

Original Article

A Comparison of the Anxiolytic and Hypnotic Effects of *Origanum majorana* Essential Oil and Alprazolam in Male Mice

Negin Manouchehri¹, Saeid Abbasi-Maleki^{2*}, Zahra Mousavi³

¹Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

²Department of Pharmacology and Toxicology, Urmia Branch, Islamic Azad University, Urmia, Iran

³ Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Received: 16.03.2019; Accepted: 16.09.2019

Abstract

Background and Aim: Previous studies have reported several pharmacological properties, including anticonvulsant, analgesic, sedative, and antidepressant-like effects, for *Origanum majorana*. Likewise, the aim of the present study was to compare the anxiolytic and hypnotic properties of *Origanum majorana* essential oil (OMEEO) and alprazolam in male mice.

Materials and Methods: In this experimental research, 60 male NMRI mice were divided into 10 groups of six mice. In both of the experiments, negative control groups received vehicle (10 ml/kg), positive control groups received alprazolam (0.5 mg/kg), and treatment groups received OMEEO (10, 20 and 40 mg/kg). For assessing the anxiolytic effects, the elevated plus maze (EPM) test was used to record the number of entries and the time spent in the open and closed arms. Moreover, the onset and duration of the sleep were recorded by the use of ketamine-induced sleeping time test in order to evaluate the hypnotic effects. Finally, one-way ANOVA, and subsequently *post hoc* Tukey's test were utilized to carry out the statistical analysis.

Results: All doses of OMEEO and alprazolam, compared to the control group, raised the number of entries and the time spent in the open arms and, conversely, decreased the number of entries and the time spent in the closed arms. Furthermore, similar to alprazolam, all doses of the essential oil reduced the onset of sleeping and raised the duration of sleep.

Conclusion: The results indicated that the OMEEO could have anxiolytic and hypnotic effects. However, further studies are required to determine their exact mechanism of action.

Keywords: *Origanum majorana*, Anxiety, Hypnotic effect, Elevated plus maze, Mice

***Corresponding Author:** Saeid Abbasi-Maleki, Department of Pharmacology & Toxicology, Urmia Branch, Islamic Azad University, Urmia, Phone +98-9141130054. Email: s.abbasi@iaurmia.ac.ir.

Please cite this article as: Manouchehri N, Saeid Abbasi-Maleki, Mousavi Z. A Comparison of the Anxiolytic and Hypnotic Effects of *Origanum majorana* Essential Oil and Alprazolam in Male Mice. *Herb. Med. J.* 2019; 4(1):18-26.

Introduction

Anxiety disorders are one of the most common

psychological problems that often lead to certain dysfunctions in the human body. This mental disorder has a negative impact on everyday activities, and

increases the risk of other disorders (1). On the other hand, insomnia is a common public health problem whose prevalence is estimated to be 10%-20% around the globe. (2).

Previous studies have indicated that several receptors, such as GABA (gamma-Aminobutyric acid), serotonin (5HT), catecholamines and sex hormones, could be influential in the pathophysiology of anxiety (3, 4). In similar studies, various neurotransmitters, such as noradrenaline (NA), histamine, acetylcholine (Ach), dopamine (DA), GABA and orexin A and B neuropeptides, play pivotal roles in the regulation of the sleep duration in the hypothalamus. (5).

Today, benzodiazepines (e.g. alprazolam) are one of the most important drugs that are used to treat anxiety and sleep disorders. These agents act as benzodiazepine receptor agonists, facilitate the entry or increase of GABA activity, and increase the entry of chloride ion into cells (6).

Alprazolam is one of the most commonly used drugs for the treatment of anxiety, insomnia, and panic disorders. Moreover, it also has muscle relaxant and anticonvulsant effects (7). Nevertheless, several side effects of benzodiazepines, including fatigue, drowsiness, dizziness, blurred vision, gradual decrease in the effects of the drug, and even the addiction and drug dependence have limited their clinical use (6). Hence, the use of drugs with few side effects, particularly alternative approaches, is warranted. Medicinal plants induce few side effects compared to synthetic drugs (8).

The *Origanum majorana* is a herb that reaches the height of 80 cm and is from the *Labiatae* family. One of the characteristics of the plant is its aromatic and strong smell. *Origanum majorana* grows in the Mediterranean region and northern Iran, particularly in Khorasan, Mazandaran, Gilan and Azarbaijan provinces. Previous studies have reported several pharmacological properties for *Origanum majorana*, including anti-Alzheimer, anti-cancer, antimicrobial, anti-inflammatory, antioxidant, antispasmodic, analgesic and hypnotic properties (9). Furthermore, we recently demonstrated the antidepressant-like activity and the effect of OMEO on morphine dependence in mice (10, 11). Apart from these findings, a study indicated the anxiolytic effects of

Origanum vulgare L. (another species of *Origanum*) in animal models of anxiety (12).

Given this and due to the lack of studies on the anxiolytic and anxiolytic effects of this plant, the aim of the present research was to compare the anxiolytic and anxiolytic effects of *Origanum majorana* essential oil (OMEO) and alprazolam in male mice.

Materials and Methods

Animals

In this experimental study, adult male NMRI mice weighing 20-30 g (purchased from Pasteur Institute, Tehran, Iran) were used. Animals were kept in cages at 23 ± 2 °C and under 12:12 h light/dark cycle. During this time, water and commercial food (Razi Vaccine and Serum Research Institute) were provided to the animals *ad libitum*. All the experiments were conducted in the light phase. In the present study, all the ethical principles were in accordance with the guidelines of the Faculty of Pharmacy and Pharmaceutical Science, Islamic Azad University, Tehran Medical Sciences Branch (IR.IAU.PS.REC.1396.140) and National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978).

Preparation of OMEO and Chemicals

The OMEO was purchased and prepared from Dr. Soleimani Pharmaceutical Company (Batch no. 006, Gorgan, Iran). Moreover, alprazolam (Rouzdaru Pharmaceutical Company, Tehran, Iran) and ketamine hydrochloride (Aflasan, Netherlands) were used. All drugs and essential oils were injected intraperitoneally (i.p.) at a constant volume of 10 ml/kg.

Elevated Plus Maze (EPM) Test

Briefly, the box consisted of two open arms ($25 \times 5 \times 30$ cm), two closed arms ($15 \times 5 \times 30$ cm), and a central section (5×5 cm). The box was made of Plexiglas and was located 60 cm above the floor. The illuminance of the open arms was 420 Lx. In this test, every mouse was individually placed at the center of the box, and during 5 min the number of entries and the time spent in the arms were recorded by a counter (Hand Tally Counter, Japan) and a chronometer (Citizen, Japan) respectively (13).

Ketamine-Induced Sleeping Time Test

To measure the sedative and hypnotic affects, the ketamine-induced sleeping time test was used. Briefly,

the intervening time between the administrations of ketamine and the loss of the righting reflex was recorded as the beginning of sleep, whereas the interval from the loss to regaining of the righting reflex was considered as the duration of sleep. In this test, the onset and duration of sleeping (time) were recorded by a chronometer in min (14).

Animal Grouping and Experimental Design

This study, in which a total 60 male NMRI mice were used, was divided into two different experiments. In the first set of the experiment, 30 mice were divided into five groups of six mice as follows:

Group I: Negative control or vehicle (normal saline with 10% Tween 80; 10ml/kg).

Groups II: Positive control or alprazolam (0.5mg/kg).

Groups III-V: treatment group or different doses of OMEO (10, 20, and 40mg/kg)

Thirty 30 min after the i.p. administration of the agents, the EPM test was conducted.

In the second set of the experiment similar to EPM test, 30 mice were divided into five groups of six mice as follows:

Group I: Negative control or vehicle (normal saline with 10% Tween 80; 10ml/kg).

Groups II: Positive control or alprazolam (0.5mg/kg).

Groups III-V= treatment group or different doses of OMEO (10, 20, and 40mg/kg).

In this set of the experiment, 30 min after the i.p. administration of the agents, the animals received ketamine (100 mg/kg, i.p.). Immediately following the ketamine injections, the onset (time) and duration of sleep were recorded.

In the present study, all essential oil and drug doses, routes of administrations, and sample size were determined on the basis of the data presented in previous literature (10, 11, 15 and 16).

Data Analysis

The data were presented as mean \pm standard deviation [S.D] (n=6) and were analyzed using the one-way analysis of variance (ANOVA) followed by *post hoc* Tukey's test. All the statistical analyses were carried out by the use of SPSS 23 software. The results were considered statistically significant at $P < 0.05$.

Results and Discussion

Anxiolytic Effects of OMEO in EPM Test

Our findings demonstrated that all doses of OMEO (10, 20, and 40 mg/kg; $P=0.078$, $P=0.019$ and $P=0.001$, respectively) as well as alprazolam (0.5 mg/kg; $P=0.003$) compared to the control (vehicle) group significantly increased the number of entries in the open arms. Moreover, there were no significant differences between the OMEO groups and alprazolam group (Figure 1).

Fig. 2 illustrates that the all doses of OMEO increased the time spent in the open arms ($P=0.001$). Furthermore, the effects (time spent in the open arms) produced by the low dose (10 mg/kg) of the essential were significantly shorter than the alprazolam group ($P=0.003$).

As it has been indicated in Fig.3, all doses of OMEO ($P=0.001$) as well as alprazolam ($P=0.001$) decreased the number of entries in the closed arms. Moreover, all doses of OMEO ($P=0.001$) as well as alprazolam ($P=0.001$) reduced the time spent in the closed arms. Nevertheless, there were no significant changes between the OEMO group and alprazolam group (Figure 4).

Hypnotic Effects of OMEO in Ketamine-Induced Sleep Test

The results showed that the onset of the sleeping time of all doses of OMEO were significantly ($P=0.001$) shorter than the control (vehicle) group, whereas all doses of the essential oil had a longer onset of sleeping than the alprazolam group ($P=0.001$) (Figure 5).

As it has been exhibited in Fig. 6, the durations of ketamine-induced sleeping time of all doses of OMEO ($P=0.023$, $P=0.000$ and $P=0.000$, respectively) as well as alprazolam ($P=0.000$) were significantly higher than the control (vehicle) group ($P < 0.05$), but all doses of the essential oil had shorter durations of sleep compared to the alprazolam group ($P=0.001$).

The results of this study indicated that all doses of the essential oil could significantly and dose-dependently increase the number of entries and time spent in the open arms in the EPM. Moreover, all doses of the essential oil could significantly and dose-dependently reduce the number of entries and time spent in the closed arms in the EPM. Hence, OMEO proved to have anxiolytic properties. Consistent with our




Figure 1. The effect of OMEO on the number of open arm entries in EPM test within 5 minutes. The results are expressed as mean ± S.D for six mice in each group. * and ** $P < 0.05$ and $P < 0.05$, compared to the control (vehicle) group, respectively. Different letters in each column indicate statistically significant difference between groups ($P < 0.05$).

ALP: Alprazolam; OMEO: *Origanum majorana* essential oil; VEH: Vehicle.




Figure 2. The effect of OMEO on the time spent in the open arms in EPM test within 5 minutes. The results are expressed as mean ± S.D for six mice in each group. *** $P < 0.001$ compared to the control (vehicle) group. Different letters in each column indicate statistically significant difference between groups ($P < 0.05$).

ALP: Alprazolam; OMEO: *Origanum majorana* essential oil; VEH: Vehicle.

findings, it has been reported that in the EPM test, the control group feel safer in the closed arms but tend to explore in the open arms (17). In addition, the exploration behavior also induces more movements of animals in the open arms of the EPM. On the contrary, animals refuse to remain in the open, illuminated, or elevated arms due to anxiety. Therefore, during anxiety, animals have the most

entries into the closed arms or spend the most time in these arms in the EPM test (18). Furthermore, in line with our results, previous studies have demonstrated that the reference drug (alprazolam) could increase the number of entries and the time spent in the open arms, and reduce the number of entries and the time spent in the closed arms (19). Hence, benzodiazepines agents (such as Alprazolam), and GABAergic activity could

increase the time spent in the open arms in the EPM, while the time spent in the closed arm of the test decreased (20).

However, GABA is one of the most significant systems involved in the pathophysiology of anxiety and exertion of hypnotic effects, and even many medicinal plants exert anxiolytic and sedative effects through the GABAergic mechanism (21- 23).

In a study concerning the phytochemical investigation of OMEO by the use of gas chromatography–mass spectrometry (GC-MS), we identified that the 4-terpineol followed by other monoterpene alcohols such as γ -terpinene, trans-sabinene hydrate, α -terpinene and α -terpineol are the major volatile compounds of OMEO (11).

Monoterpenes are the most important components of




Figure 3. Effect of OMEO on the number of closed arm entries in EPM test within 5 minutes. The results are expressed as mean \pm S.D for six mice in each group. *** $P < 0.001$ compared to the control (vehicle) group. Different letters in each column indicate statistically significant difference between groups ($P < 0.05$).

ALP: Alprazolam; OMEO: *Origanum majorana* essential oil; VEH: Vehicle.




Figure 4. The effect of OMEO on the time spent in the closed arms in EPM test within 5 minutes. The results are expressed as mean \pm S.D for six mice in each group. *** $P < 0.001$ compared to the control (vehicle) group. Different letters in each column indicate statistically significant difference between groups ($P < 0.05$).

ALP: Alprazolam; OMEO: *Origanum majorana* essential oil; VEH: Vehicle.




Figure 5. The effect of OMEO on the onset of sleeping-induced by ketamine. The results are expressed as mean ± S.D for six mice in each group; *** $P < 0.001$ compared to the control (vehicle) group. Different letters in each column indicate statistically significant difference between groups ($P < 0.05$).

ALP: Alprazolam; OMEO: *Origanum majorana* essential oil; VEH: Vehicle.




Figure 6. The effect of OMEO on the duration of sleeping-induced by ketamine. The results are expressed as mean ± S.D for six mice in each group; *** $P < 0.001$ compared to the control (vehicle) group. Different letters in each column indicate statistically significant difference between groups ($P < 0.05$).

ALP: Alprazolam; OMEO: *Origanum majorana* essential oil; VEH: Vehicle.

plant essential oils, so that many of the therapeutic and pharmacological properties of the essential oils are attributed to their monoterpenes (24). Moreover, in line with our findings, various studies have indicated that monoterpenes have anticonvulsant effects that could be mediated partly by the GABAergic system (25, 26). In a research, Yousefi

et al. exhibited that α -pinene is the major component of *Myrtus communis* essential oil (27). In another study, consistent with our findings, α -pinene, present in pine tree oil, was observed to increase the quiescent sleep, namely, non-rapid eye movement (NREM), through the mechanism of benzodiazepine GABA_A receptors. Confirming this view, the α -pinene hypnotic

effects have been reported to be completely blocked by flumazenil (a benzodiazepine GABA_A receptor antagonist) (28). In addition to these findings, and consistent with the results of our study, Satou *et al.* (2004) have also reported the anxiolytic properties of α -pinene (29).

Borneol, a bicyclic monoterpene that exists in many essential oils, is used as an analgesic and anesthetic agent in Chinese traditional medicine. This compound also exerts its effects through the mediation of GABA_A receptors (30). It has also been reported that other monoterpenes, such as verbenol and pinocarveol, are capable of enhancing the effect of GABA on GABA_A receptors (31). Consistent with our findings, it has been indicated that apigenin and limonene, two monocyclic monoterpenes, could penetrate the blood-brain barrier (BBB) and, by binding to GABA receptors, produce anxiolytic effects (32). All of these findings indicate that anxiolytic and hypnotic effects of monoterpenes are partly mediated by the GABAergic system.

Apart from the potential role of the GABAergic system in the anxiolytic and hypnotic effects of OMEO, various studies have revealed that the serotonergic system also plays a pivotal role in the anxiolytic effects of different drugs or medicinal plants. For example, in line with this view, the partial agonist of 5HT_{1A} receptors such as buspirone and ipsaperone are used in the treatment of generalized anxiety disorder (GAD). Buspirone has been reported to be more efficacious than placebo, and its ability to control anxiety is equal to those of diazepam and other benzodiazepines (33). To confirm this issue, we could refer to the fact that 5HT_{1A} receptor knockout mice showed anxiety associated with depression in behavioral models (34). Furthermore, 5HT₂ receptors are also highly influential in the pathophysiology of anxiety. In agreement with this, the 5HT₂ receptor agonist, or meta-Chlorophenylpiperazine (mCPP), has been reported to exhibit anxiogenic-like effects (35). Studies have also shown that 5HT₃ receptor antagonists produce anxiolytic effects (36).

Irrespective of the impact of serotonergic system on anxiolytic effects, certain studies have reported that the serotonergic system also plays a key role in the controlling of sleep. In this regard, the activity of these neurons decreases during rapid eye movement

(REM) sleep. In other words, blocking 5HT₂ receptors reduce REM and sleep duration (37). In this regard, our recent study demonstrated that the OMEO effects could be partly attributed to the serotonergic system. On the other hand, we indicated that the antidepressant-like effect of the OMEO could be exerted partly through the mediation of the serotonergic system. Hence, the monoterpenes in this essential oil (e.g., 4-terpineol) are likely to exert their antidepressant effect partly through mediation of the 5HT_{1A} receptors. In line with our finding, antagonizing the effect of this receptor with WAY 100135 (a selective 5HT_{1A} receptor antagonist) has been reported to block the antidepressant-like effect of the essential oil. Moreover, our recent research attributed the antidepressant-like effects of peppermint extract partly to the presence of monoterpenes, such as menthol. On the other hand, with the antidepressant effects of OMEO, the antidepressant effects of peppermint are blocked by the drug WAY-100135 (38). In a similar study, Komy *et al.* observed that volatile lemon essential oil could induce anxiolytic and antidepressant-like effects in mice. They attributed this effect mainly to the limonene, which is a monoterpene in the herb, and argued that the essential oil exerts its sedative and anxiolytic effects through mediation of 5HT_{1A} receptor (39). However, due to the role of 5HT₂ receptors in sleep pathophysiology, previous studies have attributed the antidepressant-like effects of monoterpenes partly to their effects on 5HT_{2A/C} receptors, confirmed by blocking of the antidepressant-like effects of OMEO and the crude extract of peppermint by ketanserin (5HT_{2A/C} receptor antagonist) (12, 37). Therefore, these receptors could also be involved in the essential oil's sedative effects. Nevertheless, the strengths of this study include the determination of the anxiolytic and hypnotic effects of OMEO for the first time, and its limitations include lack of determining the exact mechanism of the essential oil.

Conclusion

The results of the present study indicated the anxiolytic and hypnotic effects of OMEO. Nonetheless, further studies are required to determine their exact mechanism of action.

Acknowledgment

This study was extracted from a Pharm. D. thesis (No. 22510303952071) at the Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran. The authors express their gratitude to Rouzdaru Pharmaceutical Co. and Giah Essans Pharmaceutical Co. for providing the alprazolam and *Origanum majorana* essential oil, respectively.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- Langen B, Egerland U, Bernoster K, Dost R, Unverferth K, Rundfeldt C. Characterization in rats of the anxiolytic potential of ELB139[1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-on], a new agonist at the benzo-diazepine binding site of the GABAA receptor. *J Pharmacol Exp Ther.* 2005;314:717-24.
- Lamberg L. Insomnia shows strong link to psychiatric disorders. *Psychiatr News.* 2005; 40:21-3.
- Enoch MA. The role of GABAA receptors in the development of alcoholism. *Pharmacol Biochem Behav.* 2008; 90(1):95-104.
- Songtachalart T, Roomruangwong C, Carvalho AF, Bourin M, Maes M. Anxiety Disorders: Sex Differences in Serotonin and Tryptophan Metabolism. *Curr Top Med Chem.* 2018;18(19):1704-15.
- Ockert, W. A new dawn in the sleep disorders pipeline? *Nat Rev Drug Discov.* 2012;11:595-6.
- Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. *Ochsner J.* 2013;13(2):214-23.
- Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse, and Withdrawal. *J Addict Med.* 2018;12(1):4-10.
- Karimi A, Majlesi M, Rafeian-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. *J Nephropharmacol.* 2015;4(1):27-30.
- Salehi-Surmaghi MH: Medicinal plants and phytotherapy. 1th ed. Tehran, Donyaiekh Taghzieh Publication, 2011.
- Sadighi S, Abbasi-Maleki S, Moradi-Kor N. Evaluation of the effect of *Origanum Majorana* L. essential oil on morphine withdrawal signs in male mice. In: 1st International Conference on Medicine, Public Health and Biological Sciences (MPHBS); Sep 9-19. 2016. Tehran, Iran. Abstract 222.
- Abbasi-Maleki S, Khadhoda Z, Taghizad-Farid R. The antidepressant-like effects of *Origanum majorana* essential oil on mice through monoaminergic modulation using the forced swimming test, *Journal of Traditional and Complementary Medicine*, <https://doi.org/10.1016/j.jtcme.2019.01.003>.
- Mombeini T, Mazloui S, Shams J. Pharmacological Effects of *Origanum Vulgare* L. in the Elevated Plus- Maze and Open Field Tests in the Rat. *J Basic Clin Pathophysiol.* 2015; 3:29-36.
- Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. *Nat Protoc.* 2007;2(2):322-8.
- Vaseghi G, Andalib S, Rabbani M, Sajjadi SE, Jafarian A. Hypnotic Effect of *Salvia Reuterana* Boiss for Treatment of Insomnia. *J Med Plants.* 2013;15:7-13.
- Walle M, Walle b, Zerihun L, Makonnen E. Sedative-Hypnotic Like Effect of the Essential Oil from the Leaves of *Myrtus Communis* on Mice. *Am J Biomed Life Scis.* 2014;2(4):70-7.
- Anwar MJ, Pillai KK, Khanam R, Akhtar M, Vohora D. Effect of alprazolam on anxiety and cardiomyopathy induced by doxorubicin in mice. *Fundam Clin Pharmacol.* 2012;26(3):356-62.
- Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. *Nat Protoc.* 2007;2(2):322-8.
- Leo LM, Pamplona FA. Elevated Plus Maze Test to Assess Anxiety-like Behavior in the Mouse. *Bio-protocol.* 2014;4(16):e1211. Doi: [10.21769/BioProtoc.1211](https://doi.org/10.21769/BioProtoc.1211).
- Aryal D, Khan N. Anxiolytic and Motor Coordination Activity of Ethanolic and Aqueous Extracts of *Dendrophthoe Falcata* Leaves in Mice. *Int J Pharm Sci Res.* 2015;6(4):1753-60.
- Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. *Depress Anxiety.* 2007;24(7):495-517.
- Griffin III CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated Effects. *Ochsner J.* 2013;13(2):214-23.
- Smith KS, Engin E, Meloni EG, Rudolph U. Benzodiazepine-induced anxiolysis and reduction of conditioned fear are mediated by distinct GABA(A) receptor subtypes in mice. *Neuropharmacol.* 2012;63(2):250-8.
- Shi Y, Dong JW, Zhao JH, Tang LN, Zhang JJ. Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence. *Curr Neuropharmacol.* 2014;12(3):289-302.
- Granger RE, Campbell EL, Johnston GA(+)- And (-)-borneol: efficacious positive modulators of GABA action at human recombinant alpha1beta2gamma2L GABA(A) receptors. *Biochem Pharmacol.* 2005;69(7):1101-11.
- Nobrega FF, Salvadori MG, Masson CJ, Mello CF, Nascimento TS, Leal-Cardoso JH, et al. Monoterpenoid terpinen-4-ol exhibits anticonvulsant activity in behavioural and electrophysiological studies. *Oxid Med Cell Longev.* 2014;2014:703848.
- Wang ZJ, Heinbockel T. Essential Oils and Their Constituents Targeting the GABAergic System and Sodium Channels as Treatment of Neurological Diseases. *Molecules.* 2018;23(5):1061.
- Yousefi F, Abbasi-Maleki S, Najafi Zadeh P. The phytochemical and anesthesia effects of *Myrtus communis* essential oil co-administration with thiopental in male rat. *J Shahrekord Univ Med Sci.* 2018;20(4): 87-99.
- Yang H, Woo J, Pae AN, Um MY, Cho NC, Park KD, et al. a-pinene, a Major Constituent of Pine Tree Oils, Enhances Non-Rapid Eye Movement Sleep in Mice through GABAA-benzodiazepine Receptors. *Mol Pharmacol.* 2016;90(5):530-9.
- Satou T, Kasuya H, Maeda K, and Koike K. Daily inhalation of a-pinene in mice: effects on behavior and organ accumulation. *Phytother Res.* 2014;28:1284-7.
- Granger RE, Campbell EL, Johnston GAR. (1)- And (-)-borneol: efficacious positive modulators of GABA action at human recombinant alpha1beta2gamma2L GABA(A) receptors. *Biochem Pharmacol.* 2005;69:1101-11.
- Kessler A, Sahin-Nadeem H, Lummis SCR, Weigel I, Pischetsrieder M, Buettner A, et al. GABA(A) receptor modulation by terpenoids from *Sideritis* extracts. *Mol Nutr Food Res.* 2014;58:851-62.
- Celano M, Maggisano V, De Rose RF, Bulotta S, Maiuolo J, Navarra M, et al. Flavonoid fraction of *Citrus reticulata* juice reduces proliferation and migration of anaplastic thyroid carcinoma cells. *Nutr Cancer.* 2015;67:1183-90.
- Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. 5-

HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. *Psychopharmacology (Berl)*. 2014;231(4):623-6.

34. Toth M. 5-HT_{1A} receptor knockout mouse as a genetic model of anxiety. *Eur J Pharmacol*. 2003;463(1-3):177-84.

35. Arrant AE, Coburn E, Jacobsen J, Kuhn CM. Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats. *Neuropharmacol*. 2013;73:359-67.

36. Kurhe YV, Radhakrishnan M, Thangaraj D, Gupta D. Anti-anxiety effect of a novel 5-HT_{1A} receptor agonist (benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k)

using battery tests for anxiety in mice. *Indian J Pharmacol*. 2014;46(1):100-4.

37. Vanover KE, Davis RE. Role of 5-HT_{2A} receptor antagonists in the treatment of insomnia. *Nat Sci Sleep*. 2010; 2:139-50.

38. Abbasi-Malekia S, Bakhtiarian A, Nikoui V. Involvement of the monoaminergic system in the antidepressant-like effect of the crude extract of *Mentha piperita* (Lamiaceae) in the forced swimming test in mice. *Synergy*. 2017;5:21-8.

39. Komiya M, Takashi T, Harada E. Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice. *Brain Res*. 2006;172(2):240-49.

© **Negin Manouchehri, Saeid Abbasi-Maleki, Zahra Mousavi**. Originally published in the *Herbal Medicines Journal* (<http://www.hmj.lums.ac.ir>), 03.10.2019. This article is an open access article under the terms of Creative Commons Attribution License, (<https://creativecommons.org/licenses/by/4.0/>), the license permits unlimited use, distribution, and reproduction in any medium, provided the original work is properly cited in the *Herbal Medicines Journal*. The complete bibliographic information, a link to the original publication on <http://www.hmj.lums.ac.ir/>, as well as this copyright and license information must be included.